On Thursday, Sigma-Aldrich Corporation (NASDAQ:SIAL)’s shares inclined 0.06% to $139.56.
Aldrich Corporation (NASDAQ: SIAL) declared it has secured unconditional approval from Brazil’s Council for Economic Defense (CADE), the final outstanding approval required for the planned acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany (the “Transaction”). This clearance, which will be effective after a waiting period of 15 days, follows recently received antitrust approvals from the competition authorities of Israel (IAA) and South Korea (KFTC).
On September 22, 2014, Merck and Sigma-Aldrich declared they had reached a definitive agreement under which Merck, will acquire Sigma-Aldrich for $17 billion - $140 cash per share, establishing one of the leading players in the $130 billion global life science industry.
Sigma-Aldrich Corporation, a life science and high technology company, develops, manufactures, purchases, and distributes various chemicals, biochemicals, and equipment products worldwide. The company provides chemical products, reagents, and kits and services are used in scientific research, counting genomic and proteomic research, biotechnology, pharmaceutical development, and diagnosis of disease; and as key components in pharmaceutical, diagnostics, and high technology manufacturing. It offers media and critical raw materials for industrial cell culture, contract manufacturing services, pharmaceutical safety testing services, and organometallic precursors for semiconductor manufacturing.
St. Jude Medical, Inc. (NYSE:STJ)’s shares dropped -0.96% to $70.38.
St. Jude Medical, Inc. (STJ) will present at the Morgan Stanley Global Health Care Conference on Wednesday, Sept. 16, in New York City. Mike Rousseau, chief operating officer and Don Zurbay, vice president, finance and chief financial officer, will address the conference at 9:20 a.m. EDT.
A live webcast of the presentation will also be accessible on the St. Jude Medical Investor Relations website: investors.sjm.com
St. Jude Medical, Inc., together with its auxiliaries, develops, manufactures and distributes cardiovascular medical devices for cardiac rhythm administration, cardiovascular, and atrial fibrillation therapy areas worldwide. It operates in two divisions, Implantable Electronic Systems, and Cardiovascular and Ablation Technologies.
At the end of Thursday’s trade, RLJ Lodging Trust (NYSE:RLJ)‘s shares surged 0.13% to $27.15.
RLJ Lodging Trust ( RLJ ) stated results for the three and six months ended June 30, 2015.
Highlights
- Pro forma RevPAR raised 5.0%, Pro forma ADR raised 6.4%, and Pro forma Occupancy reduced 1.3%.
- Pro forma RevPAR raised 8.6% not taking into account New York and Houston.
- Pro forma Hotel EBITDA Margin raised 32 bps to 39.3%; 135 bps not taking into account New York and Houston.
- Pro forma Merged Hotel EBITDA raised 7.6% to $116.5 million.
- Adjusted FFO raised 4.7% to $98.1 million.
- Repurchased 2.0 million shares for $59.8 million.
RLJ Lodging Trust is an independent equity real estate investment trust. The firm also manages real estate funds. It invests in the real estate markets of the United States. The firm primarily invests in premium-branded, focused service, and compact full-service hotels. RLJ Lodging Trust was launched in 2000 and is domiciled in Bethesda, Maryland..
Nektar Therapeutics (NASDAQ:NKTR), ended its Thursday’s trading session with -2.54% loss, and closed at $11.11.
Nektar Therapeutics (NKTR) declared recently that it has received a $40 million cash payment under a license agreement with AstraZeneca. The payment was triggered by the first commercial sale of MOVENTIG (naloxegol) in Germany. MOVENTIG is the first once-daily, oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication approved in the European Union for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s). MOVENTIG is marketed in the U.S. by AstraZeneca as MOVANTIK™ (naloxegol) and is the first once-daily oral PAMORA medication indicated for the treatment of OIC in adult patients with chronic, non-cancer pain.
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline comprises drug candidates in therapeutic areas comprising oncology, pain, anti-infectives, and immunology.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
